Abstract
BACKGROUND: Immunohistochemical quantification of the immune response is prognostic for colorectal cancer (CRC). Here, we evaluate the suitability of alternative immune classifiers on prognosis and assess whether they relate to biological features amenable to targeted therapy.
METHODS: Overall survival by immune (CD3, CD4, CD8, CD20 and FOXP3) and immune-checkpoint (ICOS, IDO-1 and PD-L1) biomarkers in independent CRC cohorts was evaluated. Matched mutational and transcriptomic data were interrogated to identify associated biology.
RESULTS: Determination of immune-cold tumours by combined low-density cell counts of CD3, CD4 and CD8 immunohistochemistry constituted the best prognosticator across stage II-IV CRC, particularly in patients with stage IV disease (HR 1.98 [95% CI: 1.47-2.67]). These immune-cold CRCs were associated with tumour hypoxia, confirmed using CAIX immunohistochemistry (P = 0.0009), which may mediate disease progression through common biology (KRAS mutations, CRIS-B subtype and SPP1 mRNA overexpression).
CONCLUSIONS: Given the significantly poorer survival of immune-cold CRC patients, these data illustrate that assessment of CD4-expressing cells complements low CD3 and CD8 immunohistochemical quantification in the tumour bulk, potentially facilitating immunophenotyping of patient biopsies to predict prognosis. In addition, we found immune-cold CRCs to associate with a difficult-to-treat, poor prognosis hypoxia signature, indicating that these patients may benefit from hypoxia-targeting clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 1280-1288 |
| Number of pages | 9 |
| Journal | British Journal of Cancer |
| Volume | 123 |
| Early online date | 20 Jul 2020 |
| DOIs | |
| Publication status | Published - 13 Oct 2020 |
Bibliographical note
Acknowledgements:PQ is a National Institute of Health Research Senior Investigator.
Funding:
The funders had no role in study design, collection, data analysis, or interpretation of the data. This study was supported by a Cancer Research UK Accelerator grant and carried out in collaboration with the stratified medicine consortium in colorectal cancer (S:CORT) which is jointly funded by the Medical Research Council and Cancer Research UK.
Data availability
The data are held within the Northern Ireland Biobank and the stratified medicine consortium in colorectal cancer (S:CORT), respectively, and are available on application.
Keywords
- Cancer microenvironment
- colorectal cancer
- tumour biomarkers
- MICROENVIRONMENT
- CARCINOMA
Access to Document
- Craig_et_alBJC_ImmuneStatusIsPrognosic_VoR
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.